Vertex Pharmaceuticals initiated with a Buy at Redburn Atlantic

Redburn Atlantic initiated coverage of Vertex Pharmaceuticals with a Buy rating and $545 price target. Vertex is among the “cleanest growth stories” in global biopharma, capable of delivering low double-digit sales and mid-teens earnings growth over the next five years and “top-tier revenue visibility into the next decade,” the analyst tells investors in a research note. The firm’s physician survey work supports our above-consensus outlooks for the company’s pipeline assets including suzetrigine in pain, Casgevy in sickle cell disease and VX880 in Type 1 diabetes.